Heart FailureNCT05980585
Assessment of Heart Failure (HF) At-Home Management Solution ADI Cardio Pulmonary Monitoring System (CPM)
A study testing CPM Device in people with Heart Failure, run by Analog Device, Inc. at 1 site in United States.
Trial summary
This study is meant primarily to assess the deployment of the ADI CPM System in a clinical setting and determine interoperability of the CPM System within existing care pathways for patients with CHF. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Heart Failure
- What is being tested?
- CPM Device
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2 participants
- Where
- 1 siteUnited States
- Study dates
- 20 Apr 2022to 24 Jun 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- NYHA Class III-IV HF
- NYHA Class II HF patients with elevated BNP levels (BNP>100 pg per mL) NYHA Class II HF patients with elevated NT-proBNP levels (NT-proBNP>400 pg per mL)
- HF Patients with at least one Worsening HF event (in /out-patient) in past 12 months
- HF patients with Acute Renal Failure or Chronic Kidney Disease
- HF patients with Chronic Obstructive Pulmonary Disease (COPD)
- HF patients currently on 40 mg or more of Furosemide /
Who cannot join
- Under age 60
- End Stage Renal Disease
- Patients with severe COPD (GOLD stage III or IV)
- Limited mobility preventing application of device
- Cognitive impairments that would limit the application and proper use of the device
- Skin allergies or skin sensitivities to silicone-based adhesives
Show all 10Show fewer
- Pregnancy
- Skin breakdown on the left chest or breast area
- Not willing to shave chest hair if needed to apply device
- No cellular coverage (Patient's Home)
Trial locations and contacts
1 site in 1 country.
About this study
This study is meant primarily to assess the deployment of the ADI CPM System in a clinical setting and determine interoperability of the CPM System within existing care pathways for patients with CHF. In this initial study the CPM System will not be used to determine or support clinical decision making however post deployment the clinical study team will review patient HF events and changes in treatment during the course of the deployment and compare to the data generated by the CPM System during the study to determine the accuracy of the patient generated data as a basis for designing a more comprehensive "interventional study" to determine clinical and financial efficacy of the CPM System.
Read the detailed description
Patients will be recruited and begin the study as they are identified and consent to the study. Recruiting will end either by a designated date set at the initiation of the study or when 30 patients have been enrolled in the study.
The duration of the study for each patient will be approximately 60 days beginning with the baseline/initial visit and concluding 30 days after the patient has completed device use. The patient will use the device given to the once a day during the first 60 days the study and following that time patient records will be reviewed retrospectively for CHF events for the 60 days plus an additional 30 days after their last measurement. Each patient will also receive weekly calls from the research team to check in on device functionality and assure adherence to the protocol.
At visit 1, the start of the study, baseline information will be collected, importantly including accurate weight and notes about congestion and fluid buildup. The study will be re-described to the participant. The research team will then set up the device for the individual patient by making adjustments (as needed) to address patient specific anatomy), ensuring that the sensors are all contacting the appropriate chest areas, and confirming the measurements on the CPM Web application. The patient will be shown how to apply and replace the adhesive on the device, how to position the device, how to take a measurement with the device, and how to store the device on the Base Station. The trained provider will then register the baseline reading for the CHF device using the CHF Mobile App.
Informational materials about using the device, refreshing adhesives, and meanings of LEDs and chimes on the device will also be given to the patient. The patient will be instructed to follow the normal regimen prescribed by their by their physician, but to add taking a measurement with their CPM at the same time each day (preferably when they first wake up).
Between visits, caregivers will not have any access to the data being collected on the CHF Device. They should perform their usual standard of care on these patients. Participants will also receive calls from the research team to check in about the progress of the study (i.e., if protocols are being followed correctly, if the CPM device is working properly, and if adherence is satisfactory. This check-in, conversation topics should focus on any ease-of-use issues and address any compliance-based issues.
The ADI team will have access to data (without any patient identifying information) throughout the course of the trial, including adherence rates of patients. The sponsors will reach out to the study team if a specific patient is found to have missed 2 days in a row of measurements. The research team will contact patients directly if there is a continued trend towards non-compliance.
If a participant is having technical difficulties using the CPM System, the research team in conjunction with ADI will provide direct (in office) or remote assistance or replace existing equipment as necessary.
On visit 2, which will take place at the end of the 60 days, the research team will make arrangements for the patient to return to the office for a check-up and return the device (the same tests as described in the "physical examination" section including b lines/comet tails, dyspnea scale, etc.). Patients will also be asked about their perception on "ease of use", impact on day-to-day activities, and overall satisfaction with the CPM system. Thirty days following the last measurement the study team, will review the patients records for all HF related events and treatment changes.
- Conditions
- Heart Failure
- Being tested
- CPM Device
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CPM DeviceDevice
Daily use of the CPM wearable device
| Study group | Role | What they receive |
|---|---|---|
| Study Group | Experimental | The Study group will use the CPM device once daily (in the morning) for 60 days. Receives: Device: CPM Device |
What is being measured
The primary outcome is the main question the study is designed to answer.
Interoperability of CPM system
patient satisfaction with system obtained through survey questions; ease of use, impact and satisfaction; scale of 1-7 used with 1 being negative and 7 being positive, impact on daily life obtained though Minnesota Living with Heart Failure questionnaire
Measured: 60 days
Secondary outcomes (1)
Correlation of device data and clinical outcomes
Retrospective review of data to determine correlation of patient specific device measurements (such as increase/decrease in specific device parameters) with heart failure events. Measurements include thoracic impedance, respiration rate (RR), heart rate (HR), relative tidal volume (rTV), RR variability, HR variability, RR/rTV, QRS width, QTc width, presence of atrial fibrillation, and diastolic heart sound strength
Measured: 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Aug 2023
- Study start20 Apr 2022
- Primary completion30 Apr 2022
- Study completion24 Jun 2024
Why it stopped: Terminated due to operational considerations
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- The study looks at a single group of patients that uses the CPM Device
- Masking
- None (open label)
- Enrolment
- 2 participants (actual)
Sponsor and investigators
- Lead sponsor
- Analog Device, Inc.
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05980585
- Sponsor's protocol ID
- OBS-BAPTISTJAX
- Status last verified
- Aug 2026
- First submitted
- 26 Jul 2023
- Last updated
- 19 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Heart Failure (HF) At-Home Management Solution ADI Cardio Pulmonary Monitoring System (CPM)
- ClinicalTrials.gov ID
- NCT05980585
- Acronym / sponsor ID
- OBS-BAPTISTJAX
- Conditions
- Heart Failure
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Terminated due to operational considerations
- Enrolment
- 2 participants (actual)
- Lead sponsor
- Analog Device, Inc.University, hospital or other
- Study start
- 20 Apr 2022 (actual)
- Primary completion
- 30 Apr 2022 (actual)
- Study completion
- 24 Jun 2024 (actual)
- First posted
- 8 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is meant primarily to assess the deployment of the ADI CPM System in a clinical setting and determine interoperability of the CPM System within existing care pathways for patients with CHF. In this initial study the CPM System will not be used to determine or support clinical decision making however post deployment the clinical study team will review patient HF events and changes in treatment during the course of the deployment and compare to the data generated by the CPM System during the study to determine the accuracy of the patient generated data as a basis for designing a more comprehensive "interventional study" to determine clinical and financial efficacy of the CPM System.
Detailed description
Patients will be recruited and begin the study as they are identified and consent to the study. Recruiting will end either by a designated date set at the initiation of the study or when 30 patients have been enrolled in the study.
The duration of the study for each patient will be approximately 60 days beginning with the baseline/initial visit and concluding 30 days after the patient has completed device use. The patient will use the device given to the once a day during the first 60 days the study and following that time patient records will be reviewed retrospectively for CHF events for the 60 days plus an additional 30 days after their last measurement. Each patient will also receive weekly calls from the research team to check in on device functionality and assure adherence to the protocol.
At visit 1, the start of the study, baseline information will be collected, importantly including accurate weight and notes about congestion and fluid buildup. The study will be re-described to the participant. The research team will then set up the device for the individual patient by making adjustments (as needed) to address patient specific anatomy), ensuring that the sensors are all contacting the appropriate chest areas, and confirming the measurements on the CPM Web application. The patient will be shown how to apply and replace the adhesive on the device, how to position the device, how to take a measurement with the device, and how to store the device on the Base Station. The trained provider will then register the baseline reading for the CHF device using the CHF Mobile App.
Informational materials about using the device, refreshing adhesives, and meanings of LEDs and chimes on the device will also be given to the patient. The patient will be instructed to follow the normal regimen prescribed by their by their physician, but to add taking a measurement with their CPM at the same time each day (preferably when they first wake up).
Between visits, caregivers will not have any access to the data being collected on the CHF Device. They should perform their usual standard of care on these patients. Participants will also receive calls from the research team to check in about the progress of the study (i.e., if protocols are being followed correctly, if the CPM device is working properly, and if adherence is satisfactory. This check-in, conversation topics should focus on any ease-of-use issues and address any compliance-based issues.
The ADI team will have access to data (without any patient identifying information) throughout the course of the trial, including adherence rates of patients. The sponsors will reach out to the study team if a specific patient is found to have missed 2 days in a row of measurements. The research team will contact patients directly if there is a continued trend towards non-compliance.
If a participant is having technical difficulties using the CPM System, the research team in conjunction with ADI will provide direct (in office) or remote assistance or replace existing equipment as necessary.
On visit 2, which will take place at the end of the 60 days, the research team will make arrangements for the patient to return to the office for a check-up and return the device (the same tests as described in the "physical examination" section including b lines/comet tails, dyspnea scale, etc.). Patients will also be asked about their perception on "ease of use", impact on day-to-day activities, and overall satisfaction with the CPM system. Thirty days following the last measurement the study team, will review the patients records for all HF related events and treatment changes.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- The study looks at a single group of patients that uses the CPM Device
| Arm | Type | Receives |
|---|---|---|
| Study Group | Experimental | Device: CPM DeviceThe Study group will use the CPM device once daily (in the morning) for 60 days. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- NYHA Class III-IV HF
- NYHA Class II HF patients with elevated BNP levels (BNP>100 pg per mL) NYHA Class II HF patients with elevated NT-proBNP levels (NT-proBNP>400 pg per mL)
- HF Patients with at least one Worsening HF event (in /out-patient) in past 12 months
- HF patients with Acute Renal Failure or Chronic Kidney Disease
- HF patients with Chronic Obstructive Pulmonary Disease (COPD)
Key exclusion criteria (10 listed)
- Under age 60
- End Stage Renal Disease
- Patients with severe COPD (GOLD stage III or IV)
- Limited mobility preventing application of device
- Cognitive impairments that would limit the application and proper use of the device
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CPM DeviceDaily use of the CPM wearable device | Device | Study Group |
Primary outcome
Interoperability of CPM system
Time frame: 60 days
patient satisfaction with system obtained through survey questions; ease of use, impact and satisfaction; scale of 1-7 used with 1 being negative and 7 being positive, impact on daily life obtained though Minnesota Living with Heart Failure questionnaire
1 secondary outcome
Correlation of device data and clinical outcomes
Time frame: 90 days
Results and safety
The study was stopped early (reason given: Terminated due to operational considerations). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Heart Failure
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Recruiting
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)
Heart Failure
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CPM Device in people with Heart Failure, run by Analog Device, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Terminated due to operational considerations). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Interoperability of CPM system (time frame: 60 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026.